Clinical trial
A Double-blind Randomized, Placebo Controlled Study to Assess the Efficacy and the Safety of Eschscholtzia Californica 1000 mg Per Day in Treating Primary Insomnia During a 28 Day Treatment Duration.
NCT02183233 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind Randomized, Placebo Controlled Study to Assess the Efficacy and the Safety of Eschscholtzia Californica 1000 mg Per Day in Treating Primary Insomnia During a 28 Day Treatment Duration.
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 31, 1998
- Completion date
- Not reported
- Enrollment
- 49 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.